公开(公告)号：US20240350636A1

公开(公告)日：2024-10-24

申请号：US18757097

申请日：2024-06-27

申请人： AIM Targeted Therapies, Inc.

发明人： Glenn ABRAHMSOHN

IPC分类号： A61K47/02 ,  A61K8/19 ,  A61K8/20 ,  A61K8/22 ,  A61K8/40 ,  A61K8/43 ,  A61K8/46 ,  A61K8/49 ,  A61K8/86 ,  A61K9/00 ,  A61K9/06 ,  A61K31/155 ,  A61K31/18 ,  A61K33/40 ,  A61K47/16 ,  A61K47/26 ,  A61K47/32 ,  A61K47/42 ,  A61L15/18 ,  A61L15/20 ,  A61L15/44 ,  A61L29/08 ,  A61L29/10 ,  A61L29/16 ,  A61L31/08 ,  A61L31/16 ,  A61Q11/00 ,  A61Q17/00

CPC分类号： A61K47/02 ,  A61K8/19 ,  A61K8/20 ,  A61K8/22 ,  A61K8/40 ,  A61K8/43 ,  A61K8/466 ,  A61K8/498 ,  A61K8/86 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/06 ,  A61K31/155 ,  A61K31/18 ,  A61K33/40 ,  A61K47/16 ,  A61K47/26 ,  A61K47/32 ,  A61K47/42 ,  A61L15/18 ,  A61L15/20 ,  A61L15/44 ,  A61L29/08 ,  A61L29/106 ,  A61L29/16 ,  A61L31/08 ,  A61L31/088 ,  A61L31/16 ,  A61Q11/00 ,  A61Q17/005 ,  A61L2300/202 ,  A61L2300/206 ,  A61L2300/404 ,  A61L2300/606 ,  A61L2420/00

摘要： Therapeutic compositions, primarily for topical application, and methods of making and using the composition. Pharmaceutical compositions formulated for specific forms of administration are also provided.

公开(公告)号：US12123012B2

公开(公告)日：2024-10-22

申请号：US17104552

申请日：2020-11-25

申请人： LIGANDAL, INC.

发明人： Andre Ronald Watson ,  Christian Foster

IPC分类号： A61K48/00 ,  A61K9/00 ,  A61K9/51 ,  A61K31/40 ,  A61K31/7105 ,  A61K47/34 ,  A61K47/42 ,  A61K47/54 ,  A61K47/64 ,  A61K47/68 ,  A61P3/10 ,  A61P35/00 ,  A61P37/00 ,  B82Y5/00 ,  C12N15/10 ,  C12N15/11 ,  C12N15/85 ,  C12N15/87 ,  C12N9/22

CPC分类号： C12N15/85 ,  A61K9/0019 ,  A61K9/0085 ,  A61K9/5146 ,  A61K31/40 ,  A61K31/7105 ,  A61K47/34 ,  A61K47/42 ,  A61K47/549 ,  A61K47/64 ,  A61K47/645 ,  A61K47/6455 ,  A61K47/6807 ,  A61K48/0016 ,  A61K48/0041 ,  A61K48/0075 ,  A61P3/10 ,  A61P35/00 ,  A61P37/00 ,  B82Y5/00 ,  C12N15/102 ,  C12N15/111 ,  C12N15/87 ,  C12N9/22 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/3517 ,  C12N2320/32

摘要： Provided are methods and compositions for delivering a nucleic acid, protein, and/or ribonucleoprotein payload to a cell. Also provided are delivery molecules that include a peptide targeting ligand conjugated to a protein or nucleic acid payload (e.g., an siRNA molecule), or conjugated to a charged polymer polypeptide domain (e.g., poly-arginine such as 9R or a poly-histidine such as 6H, and the like). The targeting ligand provides for (i) targeted binding to a cell surface protein, and (ii) engagement of a long endosomal recycling pathway. As such, when the targeting ligand engages the intended cell surface protein, the delivery molecule enters the cell (e.g., via endocytosis) but is preferentially directed away from the lysosomal degradation pathway.

公开(公告)号：US12121588B2

公开(公告)日：2024-10-22

申请号：US16480792

申请日：2018-02-01

申请人： PFIZER INC.

发明人： Kaushik Dutta ,  Jose Manuel Gomes ,  Frank W. Kotch ,  Vimalkumar B. Patel ,  Amarnauth Shastrie Prashad ,  Renee L. Procopio-Melino ,  Xiaotian Zhong

IPC分类号： A61K47/42 ,  A61K47/50 ,  A61K47/64 ,  A61K47/68 ,  C07B31/00 ,  C07B33/00 ,  C07K1/00 ,  C07K16/30 ,  C07K1/107 ,  C07K1/20

CPC分类号： A61K47/6843 ,  A61K47/6855 ,  A61K47/6889 ,  C07K1/00 ,  C07K16/3015 ,  C07K1/1077 ,  C07K1/20 ,  C07K2317/14

摘要： Optimizing production of selectively capped, and uncapped, cysteines on antibodies by manipulation of cell growth conditions including the deliberate depletion of cysteine and/or cystine in the cell culture process by way of media components, batch duration, or cell density to achieve efficient production of proteins including antibody-drug-conjugates (ADCs).; conjugating a TNB-capped cysteine-containing protein by reacting it with a reducing agent capable of detaching the TNB-capping moieties from the protein without significantly reducing antibody inter-chain sulfur bonds, and conjugating reduced sulfur bonds on the protein to a payload through a reactive linking moiety.

公开(公告)号：US12115147B2

公开(公告)日：2024-10-15

申请号：US17203467

申请日：2021-03-16

申请人： Stewart Lebrun ,  Roxanne Chan ,  Sara Chavez

发明人： Stewart Lebrun ,  Roxanne Chan ,  Sara Chavez

IPC分类号： A61K31/375 ,  A61K47/02 ,  A61K47/36 ,  A61K47/42 ,  A61P27/02 ,  A61P39/06 ,  G01N33/50

CPC分类号： A61K31/375 ,  A61K47/02 ,  A61K47/36 ,  A61K47/42 ,  A61P27/02 ,  A61P39/06 ,  G01N33/502 ,  G01N33/5058 ,  G01N33/5088

摘要： The disclosure relates to formulations and methods for the in vitro testing of ocular irritants. It was discovered that adding an antioxidant formulation to in vitro ocular irritation tests, including for example, a biochemical ocular irritation test, a reconstituted human corneal epithelium (RhCE) ocular irritation test and an excised eye depth of injury (DoI) test, substantially reduces the rate of false positives without diminishing test sensitivity, resulting in more accurately predicting ocular irritancy of test substances. More particularly, the disclosed method employs relatively high physiologic concentrations of one or more antioxidants that are normally present in tears. In a variation, much higher concentrations of one or more antioxidants may provide protection against in vivo exposure to ocular irritants.

公开(公告)号：US20240325307A1

公开(公告)日：2024-10-03

申请号：US18423695

申请日：2024-01-26

申请人： The Regents of the University of California

发明人： Angela P. BLUM ,  Jacquelin K. KAMMEYER ,  Nathan C. GIANNESCHI

IPC分类号： A61K9/107 ,  A61K9/14 ,  A61K47/42 ,  A61K47/58 ,  C07K14/00 ,  C08G61/08

CPC分类号： A61K9/1075 ,  A61K9/146 ,  A61K47/42 ,  A61K47/58 ,  C07K14/001 ,  C08G61/08 ,  C08G2261/126 ,  C08G2261/1424 ,  C08G2261/1432 ,  C08G2261/148 ,  C08G2261/164 ,  C08G2261/1644 ,  C08G2261/1646 ,  C08G2261/3324 ,  C08G2261/334 ,  C08G2261/418 ,  C08G2261/80 ,  C08G2261/90 ,  C08G2261/94

摘要： Described herein, inter alia, are peptide containing polymers, and methods of making and using the same.

公开(公告)号：US12090227B2

公开(公告)日：2024-09-17

申请号：US18526168

申请日：2023-12-01

申请人： Jiangnan University ,  Standard Foods (China) Co., Ltd ,  Le Bonta Wellness Co., Ltd

发明人： Peng Zhou ,  Changshu Liu ,  Yaowei Liu ,  Tao Yang ,  Yan Zheng ,  Jianguo Liu ,  Kexin Li ,  Shuyan Lu

IPC分类号： A61K9/00 ,  A61K9/107 ,  A61K31/7028 ,  A61K47/26 ,  A61K47/42 ,  A61K47/44

CPC分类号： A61K9/1075 ,  A61K31/7028 ,  A61K47/26 ,  A61K47/42 ,  A61K47/44

摘要： The present disclosure relates to a method to improve the encapsulation efficiency and physicochemical stability of ginsenosides Rg3 and CK nano-emulsion, belonging to the field of functional emulsions. The method to improve the encapsulation efficiency and physicochemical stability of ginsenosides Rg3 and CK nano-emulsion, includes the following steps: (1) WPI, Tween 80 and water were mixed evenly according to the amount ratio of 0.5 g:0.5-0.7 g:50 mL to obtain the aqueous phase; (2) Mixing a saponin extract containing the minor ginsenosides Rg3 and CK with edible oil evenly to obtain the oil phase; (3) Mixing the aqueous phase with the oil phase, carrying out shearing dispersion to obtain coarse emulsion, and then allowing the coarse emulsion to be subjected to microfluidization homogenization to obtain an oil-in-water nano-emulsion containing the minor ginsenosides Rg3 and CK. The nano-emulsion of the disclosure has a high encapsulation efficiency of Rg3 and CK, good physicochemical stability during storage, freeze-thaw cycles, heating, and other industrial treatments, which could be used to improve the bioavailability of minor ginsenoside Rg3 and CK.

公开(公告)号：US20240293596A1

公开(公告)日：2024-09-05

申请号：US18654601

申请日：2024-05-03

申请人： Samuel E. Lynch

发明人： Samuel E. Lynch

IPC分类号： A61L26/00 ,  A61K9/00 ,  A61K9/70 ,  A61K38/18 ,  A61K47/34 ,  A61K47/42 ,  A61P17/02

CPC分类号： A61L26/0066 ,  A61K9/0014 ,  A61K9/0024 ,  A61K9/7007 ,  A61K38/1858 ,  A61K47/34 ,  A61K47/42 ,  A61L26/0023 ,  A61L26/0033 ,  A61L26/0052 ,  A61L26/0085 ,  A61L26/0095 ,  A61P17/02 ,  A61L2300/414 ,  Y02A50/30

摘要： An improvement to the effectiveness or “take” of skin grafts or tissue replacements used to treat wounds is provided. A therapeutic composition comprising recombinant human platelet-derived growth factor BB homodimer (rhPDGF-BB) and a porous biocompatible carrier is first applied to the wound surface, followed by applying a skin substitute or tissue replacements composition.

公开(公告)号：US20240293451A1

公开(公告)日：2024-09-05

申请号：US18659445

申请日：2024-05-09

申请人： TOHOKU UNIVERSITY

发明人： Osamu SUZUKI ,  Ryo HAMAI ,  Yukari SHIWAKU ,  Kaori TSUCHIYA ,  Shinki KOUYAMA

IPC分类号： A61K33/42 ,  A61K47/42 ,  A61P9/00 ,  A61P19/08

CPC分类号： A61K33/42 ,  A61K47/42 ,  A61P9/00 ,  A61P19/08

摘要： An angiogenesis material, a bone-regeneration-promoting material, a method for producing an angiogenesis material and a method for producing a bone-regeneration-promoting material which particularly improve angiogenesis capacity, angiogenesis capacity and osteogenesis capacity, are particularly effective for bone regeneration and are expected to be applied not only to bone regeneration but also to regeneration of various tissues in which angiogenesis is required are provided. These are an angiogenesis material containing a composite of a metal-octacalcium phosphate-containing material containing octacalcium phosphate and a metal element and a bioabsorbable polymer, a bone-regeneration-promoting material using the same, and production methods thereof.

公开(公告)号：US20240287146A1

公开(公告)日：2024-08-29

申请号：US18499938

申请日：2023-11-01

申请人： AMSILK GmbH ,  Ludwig-Maximilians-Universitat Munchen ,  Universitat Bayreuth

发明人： Lin ROMER ,  Ute SLOTTA ,  Julia ENGERT ,  Gerhard Winter ,  Matthias Lucke ,  Thomas Scheibel

IPC分类号： C07K14/435 ,  A61K38/00 ,  A61K39/00 ,  A61K39/385 ,  A61K47/42 ,  A61K47/64 ,  A61K47/65 ,  A61P35/00 ,  C12N15/62

CPC分类号： C07K14/43518 ,  A61K39/385 ,  A61K47/42 ,  A61K47/646 ,  A61K47/65 ,  A61P35/00 ,  C07K14/43586 ,  C12N15/62 ,  A61K38/00 ,  A61K2039/6031 ,  A61K2039/627 ,  C07K2319/40 ,  C07K2319/50

摘要： The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.

公开(公告)号：US12064471B2

公开(公告)日：2024-08-20

申请号：US17178664

申请日：2021-02-18

申请人： NUTRAMAX LABORATORIES, INC.

发明人： Brian Cornblatt ,  Grace Cornblatt ,  Anton Bzhelyansky ,  Robert Henderson

IPC分类号： A23L33/105 ,  A61K9/00 ,  A61K9/14 ,  A61K9/28 ,  A61K31/19 ,  A61K31/194 ,  A61K31/26 ,  A61K31/357 ,  A61K31/375 ,  A61K31/7028 ,  A61K31/716 ,  A61K33/06 ,  A61K36/00 ,  A61K36/06 ,  A61K36/07 ,  A61K36/28 ,  A61K36/31 ,  A61K38/47 ,  A61K45/06 ,  A61K47/42 ,  A61P3/06

CPC分类号： A61K38/47 ,  A23L33/105 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/28 ,  A61K31/19 ,  A61K31/194 ,  A61K31/26 ,  A61K31/357 ,  A61K31/375 ,  A61K31/7028 ,  A61K31/716 ,  A61K33/06 ,  A61K36/06 ,  A61K36/07 ,  A61K36/28 ,  A61K36/31 ,  A61K45/06 ,  A61K47/42 ,  A61P3/06 ,  C12Y302/01147 ,  A23V2002/00 ,  A61K36/31 ,  A61K2300/00 ,  A61K33/06 ,  A61K2300/00 ,  A61K31/7028 ,  A61K2300/00 ,  A61K38/47 ,  A61K2300/00 ,  A61K31/375 ,  A61K2300/00 ,  A61K31/26 ,  A61K2300/00 ,  A61K36/28 ,  A61K2300/00 ,  A61K36/06 ,  A61K2300/00 ,  A61K36/07 ,  A61K2300/00

摘要： The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.